Previous 10 | Next 10 |
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside cha...
NEW YORK, NY / ACCESSWIRE / December 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT). Investors who purchased Checkpoint securities are encouraged to obtain ...
2023-12-18 10:28:27 ET Shares of Checkpoint Therapeutics ( NASDAQ: CKPT ) plunged 50% in morning trading Monday after the company said the FDA had declined to approve its drug cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma, a common type of skin cancer. ...
WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic li...
2023-12-11 12:26:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example. Leading up to U.S. FDA rulings, the st...
2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted onc...
2023-11-17 17:49:49 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics For further details see: Checkpoin...
Checkpoint Therapeutics Inc. (CKPT) is expected to report $-0.85 for Q3 2023
2023-11-14 01:33:18 ET More on Checkpoint Therapeutics Seeking Alpha’s Quant Rating on Checkpoint Therapeutics Historical earnings data for Checkpoint Therapeutics Financial information for Checkpoint Therapeutics For further details see: Checkpoin...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...